| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000038767 |
| Receipt No. | R000041391 |
| Scientific Title | Effect confirmation test of probiotics food : BFF004, BFF003 for healthy adults with constipation tend - Open method - |
| Date of disclosure of the study information | 2024/03/31 |
| Last modified on | 2019/12/03 (Ver. 1) |
| Basic information | ||
| Public title | Effect confirmation test of probiotics food : BFF004, BFF003 for healthy adults with constipation tend - Open method - | |
| Acronym | Effect confirmation test of probiotics food : BFF004,BFF003 for healthy adults with constipation tend | |
| Scientific Title | Effect confirmation test of probiotics food : BFF004, BFF003 for healthy adults with constipation tend - Open method - | |
| Scientific Title:Acronym | Effect confirmation test of probiotics food : BFF004,BFF003 for healthy adults with constipation tend | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult with a tendency for constipation | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effects of test food (probiotics) on the intestinal environment of subjects with a tendency for constipation. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Defecation frequency |
| Key secondary outcomes | 16S rRNA metagenome analysis by next generation sequencer of intestinal bacterial flora.
Intestinal metabolite (metabolome analysis). Satisfaction (VAS). |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Dose comparison |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingest probiotics food:BFF004 three times a day, 1 package after meals for 2 weeks. | |
| Interventions/Control_2 | Ingest probiotics food:BFF003 three times a day, 1 package after meals for 2 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1)Males and females from 20 to 64 years of age.
(2)Subjects with a tendency for constipation at three to five times of defecation per week at the point of screening examination. (3)Subjects who can make self-judgment and are voluntarily giving written informed consent. |
|||
| Key exclusion criteria | (1)Subjects who falls in more than half a week to Bristol scale 1.
(2)Subjects who taking medicine. (3)Subjects who taking health foods which is said to improve constipation at the point of screening examination. (4)Subjects who having been taken ntestinal preparation and/or antibacterial drug within 2 weeks at the point of screening examination. (5)Subjects who are not able to stop consumption of foods containing lactic acid bacteria, bifidobacteria, natto bacteria, oligosaccharides, dietary fibers, high amount of sugar alcohol and/or other health foods including food for specified health use, which influence intestinal regulation during the study period. (6)Subjects who consuming large amounts of alcohol on a daily basis. (7)Subjects with a digestive organ disease or surgical history who has an influence on digestive absorption and defecation. (8)Subjects who are judged to be unsuitable as a subject from an answer of a subjective background questionnaire. (9)Subjects who are pregnant or breast-feeding, or have the will of pregnancy during the study period. (10)Subjects who participate in other clinical studies or who are in willing to participate to these studies using foods, drugs and/or cosmetics. (11)Subjects who are judged as unsuitable for the study by the investigator for the other reasons. |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Shinagawa Season Terrace Health Care Clinic | ||||||
| Division name | Head of medical examination department | ||||||
| Zip code | 108-0075 | ||||||
| Address | Shinagawa Season Terrace 5F, 1-2-17 Minatominami, Minato-ku, Tokyo | ||||||
| TEL | 03-3452-3381 | ||||||
| satoru_suzuki@sempos.or.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | KSO Corporation | ||||||
| Division name | Sales department | ||||||
| Zip code | 105-0023 | ||||||
| Address | 1-9-7 Shibaura, Minato-ku, Tokyo | ||||||
| TEL | 03-3452-7733 | ||||||
| Homepage URL | |||||||
| Yoshi@kso.co.jp | |||||||
| Sponsor | |
| Institute | KSO Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Biofermin Pharmaceutical Co., Ltd |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Shinagawa Season Terrace Health Care Clinic |
| Address | 1-2-17 Minatominami, Minato-ku, Tokyo |
| Tel | 03-3452-3381 |
| tomohiro_kogo@sempos.or.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 100 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041391 |